Business Context and Reporting Period
This Form 8-K was filed by IDEAYA Biosciences, Inc. on September 21, 2023. The report discloses a material corporate governance event regarding the departure of a senior executive officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes.
Material Changes
- Executive Departure: Paul A. Stone, Chief Financial Officer (CFO), voluntarily resigned effective November 10, 2023.
- Reason for Departure: Mr. Stone is resigning to pursue other business opportunities. The filing explicitly states the resignation is not related to any disagreement with the Company regarding operations, policies, or practices.
- Interim Leadership: Andres Ruiz Briseno, Senior Vice President, Head of Finance and Investor Relations, remains the principal accounting officer and will continue to lead finance and investor relations functions.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the timing of the Company's Form 10-Q filing for the third quarter, which is expected to be completed prior to Mr. Stone's effective resignation date. The Company disclaims any obligation to update these statements. Investors are directed to the Quarterly Report on Form 10-Q filed on August 10, 2023, for a description of risks and uncertainties.
Investor Verification Checklist
- Confirm the exact effective date of the CFO resignation (November 10, 2023).
- Verify the appointment of a permanent successor to the CFO role, if any, in subsequent filings.
- Review the upcoming Form 10-Q for the third quarter to assess financial performance and liquidity status.
- Monitor for any changes in the principal accounting officer role beyond the interim arrangement.